Format
Sort by

Send to

Choose Destination

Links from Books

Items: 18

1.

Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.

Vermeulen JF, van Brussel AS, Adams A, Mali WP, van der Wall E, van Diest PJ, Derksen PW.

Mol Imaging Biol. 2013 Jun;15(3):290-8. doi: 10.1007/s11307-012-0605-8.

2.

Immunophenotyping invasive breast cancer: paving the road for molecular imaging.

Vermeulen JF, van Brussel AS, van der Groep P, Morsink FH, Bult P, van der Wall E, van Diest PJ.

BMC Cancer. 2012 Jun 13;12:240. doi: 10.1186/1471-2407-12-240.

3.

In vivo bio-imaging using chlorotoxin-based conjugates.

Stroud MR, Hansen SJ, Olson JM.

Curr Pharm Des. 2011 Dec;17(38):4362-71. Review.

4.

New technologies for human cancer imaging.

Frangioni JV.

J Clin Oncol. 2008 Aug 20;26(24):4012-21. doi: 10.1200/JCO.2007.14.3065. Review.

5.

DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis.

Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D.

Mol Cancer Ther. 2008 Jun;7(6):1615-23. doi: 10.1158/1535-7163.MCT-07-2383.

6.

Involvement of CD44, a molecule with a thousand faces, in cancer dissemination.

Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV.

Semin Cancer Biol. 2008 Aug;18(4):260-7. doi: 10.1016/j.semcancer.2008.03.015. Epub 2008 Mar 29. Review.

PMID:
18467123
7.

Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.

Nestor M, Ekberg T, Dring J, van Dongen GA, Wester K, Tolmachev V, Anniko M.

Tumour Biol. 2007;28(5):253-63. Epub 2007 Nov 9.

PMID:
17992053
8.

Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.

Cheng J, Ekberg T, Engström M, Nestor M, Jensen HJ, Tolmachev V, Anniko M.

Laryngoscope. 2007 Jun;117(6):1013-8.

PMID:
17440426
9.

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K, Lundqvist H.

Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1376-87. Epub 2007 Feb 3.

PMID:
17277931
10.

In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.

Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, Tolmachev V.

Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1296-304. Epub 2005 Jul 19.

PMID:
16028065
11.

Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.

Koppe M, Schaijk Fv, Roos J, Leeuwen Pv, Heider KH, Kuthan H, Bleichrodt R.

Cancer Biother Radiopharm. 2004 Dec;19(6):720-9.

PMID:
15665619
12.

High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.

Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1645-52. Epub 2004 Jul 31.

PMID:
15290121
13.

CD44v6: a target for antibody-based cancer therapy.

Heider KH, Kuthan H, Stehle G, Munzert G.

Cancer Immunol Immunother. 2004 Jul;53(7):567-79. Epub 2004 Feb 5. Review.

PMID:
14762695
14.

In vivo near-infrared fluorescence imaging.

Frangioni JV.

Curr Opin Chem Biol. 2003 Oct;7(5):626-34. Review.

PMID:
14580568
15.

CD44: from adhesion molecules to signalling regulators.

Ponta H, Sherman L, Herrlich PA.

Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. Review.

PMID:
12511867
16.

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.

J Nucl Med. 2000 Dec;41(12):1999-2010.

17.

Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.

de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GA.

Clin Cancer Res. 1995 Jun;1(6):591-8.

18.

Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.

de Bree R, Roos JC, Plaizier MA, Quak JJ, van Kamp GJ, den Hollander W, Snow GB, van Dongen GA.

Br J Cancer. 1997;75(7):1049-60.

Items per page

Supplemental Content

Write to the Help Desk